SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
(Amendment No. 6)
Under the Securities Exchange Act of 1934*
Nabi Biopharmaceuticals
- --------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, par value $0.10 per share
- --------------------------------------------------------------------------------
(Title of Class of Securities)
629519109
- --------------------------------------------------------------------------------
(CUSIP Number of Class of Securities)
Daniel S. Loeb
Third Point LLC
390 Park Avenue
New York, NY 10022
(212) 224-7400
- --------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
Copies to:
Michael A. Schwartz, Esq.
Willkie Farr & Gallagher LLP
787 Seventh Avenue
New York, NY 10019-6099
(212) 728-8000
September 26, 2006
- --------------------------------------------------------------------------------
(Date of Event which Requires
Filing of this Schedule)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of ss.ss. 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the
following box: [ ]
NOTE: Schedules filed in paper format shall include a signed original and five
copies of the schedule, including all exhibits. See Rule 240.13d-7 for other
parties to whom copies are to be sent.
* The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
SCHEDULE 13D
- ------------------------------------------ ------------------------
CUSIP No. 629519109 Page 2 of 7 Pages
- ------------------------------------------ ------------------------
- ----------- --------------------------------------------------------------------
1 NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Third Point LLC I.D. #13-3922602
- ----------- --------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [X]
- ----------- --------------------------------------------------------------------
3 SEC USE ONLY
- ----------- --------------------------------------------------------------------
4 SOURCE OF FUNDS*
AF
- ----------- --------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO
ITEMS 2(d) or 2(e) [ ]
- ----------- --------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
- --------------------- --------- ------------------------------------------------
7 SOLE VOTING POWER
0
--------- ------------------------------------------------
NUMBER OF SHARES 8 SHARED VOTING POWER
BENEFICIALLY OWNED
BY EACH REPORTING 5,750,000
PERSON WITH --------- ------------------------------------------------
9 SOLE DISPOSITIVE POWER
0
--------- ------------------------------------------------
10 SHARED DISPOSITIVE POWER
5,750,000
- ----------- --------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON
5,750,000
- ----------- --------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES* [ ]
- ----------- --------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
9.5%
- ----------- --------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
OO
- ----------- --------------------------------------------------------------------
SCHEDULE 13D
- ------------------------------------------ ------------------------
CUSIP No. 629519109 Page 3 of 7 Pages
- ------------------------------------------ ------------------------
- ----------- --------------------------------------------------------------------
1 NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Third Point Offshore Fund, Ltd.
- ----------- --------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [X]
- ----------- --------------------------------------------------------------------
3 SEC USE ONLY
- ----------- --------------------------------------------------------------------
4 SOURCE OF FUNDS*
AF
- ----------- --------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO
ITEMS 2(d) or 2(e) [ ]
- ----------- --------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Cayman Islands
- --------------------- --------- ------------------------------------------------
7 SOLE VOTING POWER
0
--------- ------------------------------------------------
NUMBER OF SHARES 8 SHARED VOTING POWER
BENEFICIALLY OWNED
BY EACH REPORTING 3,691,500
PERSON WITH --------- ------------------------------------------------
9 SOLE DISPOSITIVE POWER
0
--------- ------------------------------------------------
10 SHARED DISPOSITIVE POWER
3,691,500
- ----------- --------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON
3,691,500
- ----------- --------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES* [ ]
- ----------- --------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
6.1%
- ----------- --------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
OO
- ----------- --------------------------------------------------------------------
SCHEDULE 13D
- ------------------------------------------ ------------------------
CUSIP No. 629519109 Page 4 of 7 Pages
- ------------------------------------------ ------------------------
- ----------- --------------------------------------------------------------------
1 NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Daniel S. Loeb
- ----------- --------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [X]
- ----------- --------------------------------------------------------------------
3 SEC USE ONLY
- ----------- --------------------------------------------------------------------
4 SOURCE OF FUNDS*
AF
- ----------- --------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO
ITEMS 2(d) or 2(e) [ ]
- ----------- --------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
United States
- --------------------- --------- ------------------------------------------------
7 SOLE VOTING POWER
0
--------- ------------------------------------------------
NUMBER OF SHARES 8 SHARED VOTING POWER
BENEFICIALLY OWNED
BY EACH REPORTING 5,750,000
PERSON WITH --------- ------------------------------------------------
9 SOLE DISPOSITIVE POWER
0
--------- ------------------------------------------------
10 SHARED DISPOSITIVE POWER
5,750,000
- ----------- --------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON
5,750,000
- ----------- --------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES* [ ]
- ----------- --------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
9.5%
- ----------- --------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
IN
- ----------- --------------------------------------------------------------------
This Amendment No. 6 (the "Amendment") amends the Schedule 13D filed on
April 17, 2006 (together with Amendment No. 1 thereto previously filed on April
27, 2006, Amendment No. 2 thereto previously filed on June 15, 2006, Amendment
No. 3 thereto previously filed on August 16, 2006, Amendment No. 4 thereto
previously filed on September 5, 2006 and Amendment No. 5 thereto previously
filed on September 14, 2006, the "Schedule 13D") and is being filed on behalf of
Third Point LLC, a Delaware limited liability company (the "Management
Company"), Third Point Offshore Fund, Ltd., a Cayman Islands limited liability
exempted company (the "Offshore Fund"), and Daniel S. Loeb, an individual ("Mr.
Loeb" and, together with the Management Company and the Offshore Fund, the
"Reporting Persons"). Unless the context otherwise requires, references herein
to the "Common Stock" are to shares of common stock, par value $0.10 per share,
of Nabi Biopharmaceuticals, a Delaware corporation (the "Company"). The
Management Company is the investment manager or adviser to a variety of hedge
funds and managed accounts (such funds and accounts, collectively, including but
not limited to the Offshore Fund, the "Funds"). The Funds directly own the
Common Stock to which this Schedule 13D relates, and the Reporting Persons may
be deemed to have beneficial ownership over such Common Stock by virtue of their
ownership or the authority granted to them by the Funds to vote and to dispose
of the securities held by the Funds, including the Common Stock.
Item 4. Purpose of Transaction.
Item 4 of the Schedule 13D is hereby amended by adding the following
thereto:
Over a period of approximately seven months, the Reporting Persons have
encouraged the Company and its Board of Directors to explore strategic
alternatives in order to maximize value for all shareholders. The Reporting
Persons have repeatedly expressed to the Company and the Board their belief and
concern that the Company's "cash burn" rate is too high and its strategic plan
is too risky for the Company to continue with "business as usual." Of particular
concern to the Reporting Persons are that the Company does not appear to have
been receptive to interest from prospective buyers of the Company or its
component assets, and the possibilities that the Company may have to sell
valuable assets at inadequate prices or enter into dilutive equity-linked
financings in order to follow through on its business plan.
On September 14, 2006, in advance of a Board meeting scheduled for the
following day, the Reporting Persons once again called upon the Board of
Directors to expand its investment
5
bankers' mandate to allow them to explore all ways to maximize the value of the
Company's assets. Since that Board meeting, the Company has refused to comment
on whether it is moving toward a strategic alternatives process or whether some
other decision was taken by the Board.
As a result, the Reporting Persons intend to conduct shortly a consent
solicitation in order to remove Mr. McLain and possibly one or more other
directors from the Board of Directors. In conjunction with this solicitation,
the Reporting Persons also intend to solicit consents in favor of a proposal
requesting that one or more individuals named by the Reporting Persons be added
to the Board to fill any vacancies created by the removal of directors.
Under the Delaware General Corporation Law (the "DGCL") and the Company's
Certificate of Incorporation (the "Certificate"), the shareholders of the
Company are entitled to act by written consent to remove directors of the
Company. The written consent procedure to remove directors operates outside of
annual or special meetings of shareholders and may be undertaken at any time.
Although a provision of the Company's Bylaws (the "Bylaws") purports to limit
the removal of Company directors to instances of "cause" and to require a 75%
vote of the shareholders to effect such a removal, the Reporting Persons believe
that this Bylaw provision is invalid and ineffective because it conflicts with
the DGCL. Under the DGCL, except in cases not relevant to the Company and except
where the right is limited in the Certificate (not the Bylaws), the Company's
shareholders have a right to remove any or all Company directors, without cause,
by the vote of the holders of a majority of the shares of Common Stock
outstanding. The Certificate does not restrict this statutory right of the
shareholders to remove directors of the Company by majority vote and without
cause.
The Reporting Persons believe, however, that under the DGCL and the Bylaws,
the remaining members of the Board of Directors, and not the shareholders, have
the right to fill any vacancies created by the removal of directors.
Accordingly, the Reporting Persons also intend to solicit consents, at the same
time as consents are solicited for the removal of Mr. McLain and possibly one or
more other directors, in favor of a resolution of the shareholders of the
Company calling on the Board to fill the vacancies with individuals who will be
named by the Reporting Persons at the time of the consent solicitation.
* * * *
In connection with the consent solicitation, Third Point LLC and certain of
its affiliates intend to file a consent statement with the Securities and
Exchange Commission (the "SEC") to solicit stockholders of the Company with
respect to the removal of Mr. McLain and possibly one or more other directors
from the Board of Directors. THIRD POINT LLC STRONGLY ADVISES ALL
6
STOCKHOLDERS OF THE COMPANY TO READ THE CONSENT STATEMENT WHEN IT BECOMES
AVAILABLE BECAUSE IT WILL CONTAIN IMPORTANT INFORMATION, INCLUDING INFORMATION
RELATING TO THE PARTICIPANTS IN ANY SUCH CONSENT SOLICITATION. SUCH CONSENT
STATEMENT, WHEN FILED, AND ANY OTHER RELEVANT DOCUMENTS WILL BE AVAILABLE AT NO
CHARGE ON THE SEC'S WEBSITE AT HTTP://WWW.SEC.GOV.
THIRD POINT PARTICIPANT INFORMATION
In accordance with Rule 14a-12(a)(1)(i) of the Securities Exchange Act of
1934, as amended, the following persons are anticipated to be, or may be deemed
to be, participants in any such consent solicitation by Third Point LLC: Third
Point LLC, Mr. Loeb, Third Point Offshore Fund Ltd., Third Point Ultra Ltd.,
Third Point Partners LP, Third Point Qualified LP. and Lyxor/Third Point Fund
Ltd. Certain of these persons hold direct or indirect interests as follows:
Third Point LLC may be deemed to beneficially own 5,750,000 shares of Common
Stock; Mr. Daniel Loeb may be deemed to beneficially own 5,750,000 shares of
Common Stock; Third Point Offshore Fund Ltd. may be deemed to beneficially own
3,691,500 shares of Common Stock; Third Point Ultra Ltd. may be deemed to
beneficially own 621,600 shares of Common Stock; Third Point Partners LP may be
deemed to beneficially own 616,300 shares of Common Stock; Third Point Qualified
LP may be deemed to beneficially own 458,400 shares of Common Stock; and
Lyxor/Third Point Fund Ltd. may be deemed to beneficially own 362,200 shares of
Common Stock.
7
SIGNATURES
After reasonable inquiry and to the best of our knowledge and belief, the
undersigned certify that the information set forth in this statement is true,
complete and correct.
Dated: September 26, 2006
THIRD POINT LLC
By: /s/ Daniel S. Loeb
----------------------------------------
Name: Daniel S. Loeb
Title: Chief Executive Officer
THIRD POINT OFFSHORE FUND, LTD.
By: /s/ Daniel S. Loeb
----------------------------------------
Name: Daniel S. Loeb
Title: Director
/s/ Daniel S. Loeb
----------------------------------------------
Daniel S. Loeb
[SIGNATURE PAGE TO AMENDMENT NO. 6 TO SCHEDULE 13D
WITH RESPECT TO NABI BIOPHARMACEUTICALS]